The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax

ConclusionEx vivo treatment of primary CLL cells with SRF231 led to dual antitumor effects of tumor cell-extrinsic plus -intrinsic mechanisms by augmenting rituximab-induced phagocytosis and inducing tumor cell death. SRF231 induced death of tumor cells through a caspase-independent mechanism that depends at least partially on PLC. In vivo, SRF231 in combination with VEN led to complete and durable tumor regression in a xenograft model. SRF231 is currently being evaluated across multiple tumor types in a Phase 1 clinical trial (NCT03512340).DisclosuresValentin: Roche: Other: Travel reimbursement; AbbVie: Other: Travel reimbursement. Peluso: Surface Oncology: Employment, Equity Ownership. Adam: Surface Oncology: Employment, Equity Ownership. Zhang: Surface Oncology: Employment, Equity Ownership. Armet: Surface Oncology: Employment, Equity Ownership. Guerriero: GSK: Research Funding; Eli Lilly: Research Funding. Lee: Surface Oncology: Employment, Equity Ownership. Palombella: Surface Oncology: Employment, Equity Ownership. Holland: Surface Oncology: Employment, Equity Ownership. Paterson: Surface Oncology: Employment, Equity Ownership. Davids: Surface Oncology: Research Funding; Celgene: Consultancy; Verastem: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; MEI Pharma: Consultancy, Research Funding; Pharmacyclics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche/Genentec...

Source: Blood - November 21, 2018 Category: Hematology Authors: Valentin, R., Peluso, M. O., Lehmberg, T. Z., Adam, A., Zhang, L., Armet, C. M., Guerriero, J. L., Lee, B. H., Palombella, V. J., Holland, P. M., Paterson, A. M., Davids, M. S. Tags: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III Source Type: research